Expert Perspective on Implementing HCV Treatment as Prevention in At-Risk European Populations

This interactive multimedia module, designed for healthcare providers in Europe, highlights treatment as prevention as a strategy to reduce HCV incidence in persons who inject drugs.
Graham R. Foster, FRCP, PhD
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 27, 2019 Expiration: March 26, 2020
Multimedia Expert Perspective on Implementing HCV Treatment as Prevention in At-Risk European Populations
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Who Should Be Treated for HCV? (5 mins)
Review the current status of the HCV epidemic in Europe and key characteristics of the regional PWID population.
Launch Who Should Be Treated for HCV? (5 mins)
Why Should PWID Be Treated? (10 mins)
Consider the behavioural and societal benefits that accompany HCV treatment as prevention and EASL guidance on this approach.
Launch Why Should PWID Be Treated? (10 mins)
How Should PWID Be Treated? (32 mins)
Learn the essential components of PWID care and how to implement them.
Launch How Should PWID Be Treated? (32 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply strategies to increase engagement of underserved populations through HCV screening, diagnosis, and treatment programmes
  • Demonstrate the impact of HCV treatment as prevention on HCV elimination goals nationally and internationally
  • Implement harm reduction, screening, and support services for at-risk persons following HCV cure

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
INHSU Logo
Supported by an educational grant from
Gilead Sciences

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Graham R. Foster, FRCP, PhD

Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Graham R. Foster, FRCP, PhD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, GlaxoSmithKline, Merck, and Roche and has ownership interest in GlaxoSmithKline.

Staff

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME/CE services from Genomic Health, Lilly, and Merck.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers, particularly those in France, Germany, Italy, Spain, the United Kingdom, and other European countries, who care for patients with HCV infection.

Goal

The goal of this activity is to improve participants’ understanding of and competence in implementing principles of HCV treatment as prevention among key patient populations.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 27, 2019, through March 26, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable PDF resource from CCO on opioid use disorder treatment essentials for hepatologists and ID specialists managing HCV and/or HIV infection

Jenna Butner, MD Released: May 7, 2020

Latest data and best practice guidance on treating HCV in addiction medicine settings published by Clinical Care Options (CCO)

Andrew Seaman, MD Released: February 24, 2020

Expert commentary from CCO on how providers can act as advocates for increased access to HCV care for persons who use drugs and incarcerated individuals

Oluwaseun Falade-Nwulia, MBBS, MPH Released: December 18, 2019

Watch this video from a live symposium for expert guidance on approaches to improve diagnosis and treatment of HCV, HBV, and NASH.

Paul Y. Kwo, MD
Program Director
Manal F. Abdelmalek, MD, MPH Oluwaseun Falade-Nwulia, MBBS, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits US Physicians: maximum of 1.5 Medical Knowledge MOC point(s) Released: December 17, 2019 Expired: December 16, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?